Advances in sarcopenia: mechanisms, therapeutic targets, and intervention strategies
- PMID: 38592582
 - DOI: 10.1007/s12272-024-01493-2
 
Advances in sarcopenia: mechanisms, therapeutic targets, and intervention strategies
Abstract
Sarcopenia is a multifactorial condition characterized by loss of muscle mass. It poses significant health risks in older adults worldwide. Both pharmacological and non-pharmacological approaches are reported to address this disease. Certain dietary patterns, such as adequate energy intake and essential amino acids, have shown positive outcomes in preserving muscle function. Various medications, including myostatin inhibitors, growth hormones, and activin type II receptor inhibitors, have been evaluated for their effectiveness in managing sarcopenia. However, it is important to consider the variable efficacy and potential side effects associated with these treatments. There are currently no drugs approved by the Food and Drug Administration for sarcopenia. The ongoing research aims to develop more effective strategies in the future. Our review of research on disease mechanisms and drug development will be a valuable contribution to future research endeavors.
Keywords: Mechanism; Medication; Muscle; Myostatin; Receptor; Sarcopenia.
© 2024. The Pharmaceutical Society of Korea.
References
- 
    
- Abe S, Ezaki O, Suzuki M (2016) Medium-chain triglycerides in combination with leucine and vitamin D Increase muscle strength and function in frail elderly adults in a randomized controlled trial. J Nutr 146:1017–1026. https://doi.org/10.3945/jn.115.228965 - DOI - PubMed
 
 - 
    
- Adams V, Bowen TS, Werner S, Barthel P, Amberger C, Konzer A, Graumann J, Sehr P, Lewis J, Provaznik J, Benes V, Büttner P, Gasch A, Mangner N, Witt CC, Labeit D, Linke A, Labeit S (2019) Small-molecule-mediated chemical knock-down of MuRF1/MuRF2 and attenuation of diaphragm dysfunction in chronic heart failure. J Cachexia Sarcopenia Muscle 10:1102–1115. https://doi.org/10.1002/jcsm.12448 - DOI - PubMed - PMC
 
 - 
    
- Adams V, Gußen V, Zozulya S, Cruz A, Moriscot A, Linke A, Labeit S (2020) Small-molecule chemical knockdown of MuRF1 in melanoma bearing mice attenuates tumor cachexia associated myopathy. Cells 9:2272. https://doi.org/10.3390/cells9102272 - DOI - PubMed - PMC
 
 - 
    
- Agapova OA, Fang Y, Sugatani T, Seifert ME, Hruska KA (2016) Ligand trap for the activin type IIA receptor protects against vascular disease and renal fibrosis in mice with chronic kidney disease. Kidney Int 89:1231–1243. https://doi.org/10.1016/j.kint.2016.02.002 - DOI - PubMed - PMC
 
 - 
    
- Alway SE, Mccrory JL, Kearcher K, Vickers A, Frear B, Gilleland DL, Bonner DE, Thomas JM, Donley DA, Lively MW, Mohamed JS (2017a) Resveratrol enhances exercise-induced cellular and functional adaptations of skeletal muscle in older men and women. J Gerontol Biol Sci Med Sci 72:1595–1606. https://doi.org/10.1093/gerona/glx089 - DOI
 
 
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
